La vendita allo scoperto per UTime dà agli investitori un'idea del grado in cui gli investitori stanno scommettendo sul declino delle azioni di UTime. I dati relativi alle vendite allo scoperto vengono aggiornati ogni due settimane.

UTime (NASDAQ:WTO) Azioni, Report sulle vendite allo scoperto

UTime

UTime Ltd is engaged in the design, development, production, sales and brand operation of mobile phones, accessories and related consumer electronics. It also provides Electronics Manufacturing Services (EMS), including Original Equipment Manufacturer (OEM) and Original Design Manufacturer (ODM) services, for renowned brands. The company operates in China and its products are sold globally, including Mexico, Brazil, the United States, and other emerging markets in South Asia and Africa as well as Europe. It has two in-house brands, UTime, known as its middle-to-high end label and targets middle class consumers from emerging markets; and Do, as its low- to mid-end brand, is positioned to the grassroots consumers and price-sensitive consumers in emerging markets.

UTime Ltd

WIIM

BORR

Borr Drilling shares are trading lower after the company announced a $100 million offering of approximately 50 million shares.

Borr Drilling Limited (the "Company") (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BORR#NYSE">BORR</a>) announces today its plans for a public offering seeking to raise $100 million in gross proceeds though an offering of approximately 50 million shares.
The Company plans to use the proceeds from the offering for general corporate purposes, which may include debt service, capital expenditures and funding of working capital.
DNB Carnegie, Clarksons Securities, Citigroup and Goldman Sachs &amp; Co. LLC are joint bookrunners for the offering.

News

Offerings

Borr Drilling Launches $100M Public Offering Of ~50M Shares To Fund Corporate Needs, Including Debt And Capital Expenditures

Mercury Systems, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MRCY#NASDAQ">MRCY</a>, <a href="http://www.mrcy.com/">www.mrcy.com</a>))), a technology company that delivers mission-critical processing to the edge, today announced it has been selected by the U.S. Department of Defense (DoD) for funding through its Industrial Base Analysis and Sustainment (IBAS) Program to develop a next-generation RF signal conditioning multi-chip package (MCP). The IBAS Program aims to improve the readiness and competitiveness of the defense industrial base through investments in high-priority domestic technologies and supply chains.
Under a two-year, $8.5 million contract with commercial partner Systems Innovation Engineering, Mercury will develop and demonstrate a new solution designed to enhance the performance and cost of X-band Active Electronically Steered Array (AESA) radars used in air, sea, and ground-based applications. This ultra-compact signal conditioning package will leverage Mercury expertise and innovation in microwave and mixed signal technologies to reduce the size, weight, and power requirements of these integrated assemblies by more than 80% compared to existing hardware. By leveraging state-of-the-art processes, this capability will be more producible, affordability will be improved, and high-volume missions will be enabled.

MRCY

Mercury Systems Chosen By U.S. DoD For $8.5M IBAS Funding To Develop Next-Gen RF Signal Conditioning Multi-Chip Package

UMH Properties, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/UMH#NYSE">UMH</a>, TASE: UMH))) closed on the acquisition of two manufactured home communities, located in Conowingo, Maryland, for a total purchase price of $14.625 million. These communities contain 191 developed homesites, of which 79% are occupied. They are situated on approximately 82 acres.

UMH Properties Closes Acquisition Of Two Manufactured Home Communities, Located In Conowingo, Maryland, For A Total Purchase Price Of $14.625M

Gold may have dominated headlines during the first half of 2025, rising more than 25%, but it is no longer the sole shiny option for investors. While gold&#8217;s sharp growth is starting to raise valuation questions, a more subdued shift is underway in silver, platinum, and even palladium. <a href="https://www.benzinga.com/etfs">ETFs that </a><a href="https://www.benzinga.com/etfs" target="_blank" rel="noopener">track these</a> less-watched metals are gaining popularity, driven by a combination of macroeconomic tailwinds, a weakening U.S. dollar, and speculation surrounding the Fed&#8217;s next move.
Also Read: <a href="https://www.benzinga.com/etfs/specialty-etfs/25/07/46231169/these-etfs-gain-as-dollar-slips-and-rate-cut-bets-rise">These ETFs Gain As Dollar Slips And Rate Cut Bets Rise</a>
<h2 class="wp-block-heading">The Gold Standard, Still?</h2>
Gold&#8217;s rise has been impressive. The SPDR Gold Shares ETF (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GLD#NYSE">GLD</a>), the biggest and most liquid bullion-backed ETF, increased almost 26% year-to-date, even touching all-time highs in April. Its rally has been driven by rate-cut hopes, geopolitical tensions, and a dollar that&#8217;s lost 11%—its worst first-half performance in over three decades.
But there&#8217;s a caveat. RBC Capital Markets warned in April that gold may now be overpriced from a macroeconomic perspective. The rally, the analysts contend, has been fueled more by fear than by fundamentals. And fear, unlike bullion, doesn&#8217;t come with an ounce measurement.
Also Read: <a href="https://www.benzinga.com/etfs/specialty-etfs/25/06/45869385/silvers-35-breakout-the-best-etfs-for-the-bullish-ride">Silver&#8217;s $35 Breakout: The Best ETFs For The Bullish Ride</a>
<h2 class="wp-block-heading">Platinum, Silver Step Into The Spotlight</h2>
While that&#8217;s happening, other precious metals are making their own comeback. Platinum leaped more than 26% in June alone. Constrained supply conditions and a jump in demand from Chinese jewelry markets have fueled the surge. Mix in speculative demand from both the U.S. and China, and you&#8217;ve got a metal playing catch-up.
Silver and palladium aren&#8217;t quiet either. The iShares Silver Trust (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SLV#NYSE">SLV</a>) and Sprott Physical Silver Trust (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PSLV#NYSE">PSLV</a>) rose consistently as <a href="https://www.benzinga.com/analyst-stock-ratings/analyst-color/25/06/45847216/silver-supercycle-you-never-have-enough-of-it-hedge-fund-analyst-says-as-50-level-looms">investors search for discounted alternatives</a> to gold. Silver&#8217;s dual position as both an industrial metal and a precious metal lends it a unique appeal in the current climate, where inflation risk persists and economic statistics are mixed.
This volatile environment has generated a surge in interest in diversified and targeted metals ETFs. Prices of the Aberdeen Standard Physical Platinum Shares ETF (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PPLT#NYSE">PPLT</a>) and Sprott Physical Platinum and Palladium Trust (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SPPP#NYSE">SPPP</a>) have shot up in the first half of this year, suggesting increased flows, while the Invesco DB Precious Metals Fund (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DBP#NYSE">DBP</a>), holding a blend of gold and silver futures, is growing in popularity among tactical asset allocators.
At the same time, multi-metal mining ETFs, such as the iShares MSCI Global Metals &amp; Mining Producers ETF (BATS:<a class="ticker" href="https://www.benzinga.com/stock/PICK#BATS">PICK</a>), are gaining traction among investors seeking exposure to commodity prices indirectly through producers and refiners.
<h2 class="wp-block-heading">What&#8217;s Behind The Move?</h2>
Dollar Weakness: As the <a href="https://www.benzinga.com/topic/us-dollar">greenback </a>hits <a href="https://www.benzinga.com/markets/economic-data/25/06/46146713/trump-dollar-outlook-tariffs-debt">multi-decade lows</a>, dollar-denominated assets such as precious metals gain attractiveness.
Rate-Cut Buzz: Markets are expecting at least two Fed rate cuts this year, a situation that traditionally favors metal prices.
Valuation Catch-Up: Metals such as platinum remain significantly below all-time highs and are attractive on a relative basis.
<h2 class="wp-block-heading">From Gold to What's Next</h2>
If the first six months of 2025 belonged to gold, then the second half could be remembered for what comes after it. Whether it&#8217;s the breakout of silver, the rise of platinum, or a strategic blend of metals, ETF investors appear poised to diversify through uncertainty, one ounce at a time.
Read Next:<a href="https://www.benzinga.com/etfs/broad-u-s-equity-etfs/25/07/46231393/trumps-tax-blitz-is-an-etf-game-changer-are-you-ready"> </a>
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/etfs/broad-u-s-equity-etfs/25/07/46231393/trumps-tax-blitz-is-an-etf-game-changer-are-you-ready">Trump&#8217;s Tax Blitz Is An ETF Game-Changer—Are You Ready?</a></li>
</ul>
Photo: Shutterstock

Sector ETFs

Commodities

ETFs

PICK

PPLT

PSLV

SPPP

Gold Isn't The Only Game In Town—Precious Metals ETFs Are Casting A Wider Net

<ul>
<li>Implemented a workforce reduction of approximately 25% of current and planned roles in July 2025, primarily in the areas supporting early-stage research and development and support functions.</li>
<li>The workforce reduction is expected to provide annual cash compensation cost savings of approximately $15 million and offsets additional expenses expected based on the accelerated timelines for the 4FRONT clinical trials and BLA preparation, which supports the Company's cash runway into 2028, as previously guided.</li>
</ul>

Management

FDMT

4D Molecular Therapeutics Cuts Workforce By 25% In July 2025 To Save $15M Annually, Extend Cash Runway Into 2028

General

ELEV

Elevation Oncology License Agreement With CSPC Megalith Biopharmaceutical Terminated As Of June 26, 2025; Termination Agreement Includes Mutual Release Of Claims

MIRA

MIRA Pharmaceuticals shares are trading higher after the company announced preclinical results for Mira-55.

Orbic proposal remains conditional, uncertain, and unlikely to maximize value for Sonim stockholders
San Diego, California--(Newsfile Corp. - July 2, 2025) - Sonim Technologies (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SONM#NASDAQ">SONM</a>) today announced that its Special Committee of the Board of Directors (the "Special Committee") has considered, with advice from its financial advisor and legal counsel, the unsolicited, non-binding proposal from Orbic North America, LLC ("Orbic") dated June 26, 2025, and has determined it to be inferior to the previously announced Letter of Intent (the "Social Mobile LOI") between Sonim and Social Mobile for the sale of substantially all of Sonim's operating assets. The Special Committee remains committed to maximizing stockholder value and believes the Social Mobile LOI represents a superior alternative.

SONM

Sonim Technologies Special Committee Determines Latest Orbic Proposal Inferior To Social Mobile LOI

On June 27, 2025, Uneek Mehra informed 4D Molecular Therapeutics, Inc. (the "Company") of his intent to resign as Chief Financial and Business Officer of the Company effective as of July 15, 2025 in order to pursue other opportunities.
To facilitate the transition of his responsibilities, Mr. Mehra has agreed to provide advisory services and remain as the Company's principal financial officer and principal accounting officer through September 2025 and at least through the date of the filing of the Company's Quarterly Report on Form 10-Q for quarter ended June 30, 2025. Mr. Mehra's departure is not the result of any disagreement regarding the Company's operations, financial statements, guidance, corporate outlook, internal controls, auditors, policies or practices. The Company has initiated a search to identify a successor.

4D Molecular Therapeutics CFO Uneek Mehra To Resign Effective July 15, 2025

Inventiva shares are trading higher after the company published Phase 2b data from its NATIVE trial in the Journal of Hepatology.

EYEN

Hyperion Defi Enters Separation Agreement With COO Bren Kern

Mr. Cooper Gr (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/COOP#NASDAQ">COOP</a>) has outperformed the market over the past 10 years by 6.03% on an annualized basis producing an average annual return of 17.58%. Currently, Mr. Cooper Gr has a market capitalization of $9.82 billion. 
Buying $1000 In COOP: If an investor had bought $1000 of COOP stock 10 years ago, it would be worth $4,953.84 today based on a price of $153.51 for COOP at the time of writing.
<h3>Mr. Cooper Gr's Performance Over Last 10 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1751487571_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Trading Ideas

COOP

If You Invested $1000 In This Stock 10 Years Ago, You Would Have This Much Today

Representative <a href="https://www.benzinga.com/topic/alexandria-ocasio-cortez">Alexandria Ocasio-Cortez</a> (D-NY) blasted the <a href="https://www.benzinga.com/news/financing/25/07/46215975/trumps-big-beautiful-bill-offers-seniors-a-6000-bonus-tax-deduction-heres-how-you-qualify-for-the-benefit">Trump administration&#8217;s proposed tax bill</a> during a session in the House of Representatives on Wednesday, sharply criticizing a provision that eliminates taxes on tips. She warned that the provision, which Trump has portrayed as a &#8220;pro-labor&#8221; initiative, does not live up to its promise when weighed against the other damaging aspects of the bill.
"On this point of tax on tips, as one of the only people in this body who has lived off of tips, I want to tell you a little bit about the scam of that text, a little bit of the fine print there," Ocasio-Cortez <a href="https://m.economictimes.com/news/international/world-news/to-give-musk-a-tax-break-alexandria-ocasio-cortez-explodes-at-trump-over-big-beautiful-bill/amp_podcast/122211707.cms">said</a>, addressing her colleagues. "The cap on that is $25,000. While you're jacking up taxes on people who make less than $50,000 across the United States while taking away their SNAP, while taking away their Medicaid, while kicking them off of the ACA and their health care extensions."
On Tuesday, Senate Republicans narrowly <a href="https://www.benzinga.com/news/politics/25/07/46211326/one-big-beautiful-bill-passes-senate-with-jd-vances-tie-breaking-vote-trump-says-its-going-to-go-very-nicely-in-the-house">passed</a> Trump&#8217;s massive tax and spending bill, which could add&nbsp;$3.3 trillion to the national&nbsp;debt. 
<h2 class="wp-block-heading">&#8216;Deal With The Devil&#8217; &#8211; Tax Cuts For Elon Musk, Other Billionaires</h2>
Ocasio-Cortez explained that while the provision might sound beneficial, it comes with hidden costs that could negatively affect low-income workers. She pointed to the stark choices facing workers who rely on tips to make a living. 
"So, if you're at home and you're living off tips, you do the math. Is that worth it to you? Losing all your health care? Not being able to feed your babies? Not being able to put a diaper on their bottom, in exchange for what?&#8221; 
She denounced the bill as a &#8220;deal with the devil,&#8221; arguing that it will only worsen the nation&#8217;s financial state by ballooning the national debt, militarizing the economy and stripping away basic services. &#8220;It explodes our national debt, it militarizes our entire economy, and it strips away health care and basic dignity of the American people for what? To give Elon Musk a tax break and billionaires the greedy taking of our nation? We can not stand for it, and we will not support it. You should be ashamed."
House Speaker Mike Johnson is working to meet a July 4 deadline.
Photo: Shutterstock

Government

Politics

Alexandria Ocasio-Cortez Bashes Trump's 'No Tax On Tips' Bill Provision As 'Scam'

MCHP

Steve Sanghi Will Continue To Serve As Microchip CEO And President On A Permanent Basis

4 analysts have shared their evaluations of Elanco Animal Health (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ELAN#NYSE">ELAN</a>) during the recent three months, expressing a mix of bullish and bearish perspectives.
The table below offers a condensed view of their recent ratings, showcasing the changing sentiments over the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">4</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
Analysts have recently evaluated Elanco Animal Health and provided 12-month price targets. The average target is $15.25, accompanied by a high estimate of $17.00 and a low estimate of $13.00. Marking an increase of 3.39%, the current average surpasses the previous average price target of $14.75. 
<img src="https://www.benzinga.com/files/images/story/2025/1751487492_0.png" alt="price target chart" />
<h2>Understanding Analyst Ratings: A Comprehensive Breakdown</h2>
The standing of Elanco Animal Health among financial experts becomes clear with a thorough analysis of recent analyst actions. The summary below outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Jonathan Block</td>
<td>Stifel</td>
<td>Raises</td>
<td>Buy</td>
<td>$17.00</td>
<td>$16.00</td>
</tr>
<tr>
<td>Jonathan Block</td>
<td>Stifel</td>
<td>Raises</td>
<td>Buy</td>
<td>$16.00</td>
<td>$15.00</td>
</tr>
<tr>
<td>Jonathan Block</td>
<td>Stifel</td>
<td>Raises</td>
<td>Buy</td>
<td>$15.00</td>
<td>$13.00</td>
</tr>
<tr>
<td>Jonathan Block</td>
<td>Stifel</td>
<td>Lowers</td>
<td>Buy</td>
<td>$13.00</td>
<td>$15.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Responding to changing market dynamics and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their response to recent developments related to Elanco Animal Health. This offers insight into analysts' perspectives on the current state of the company.</li>
<li>Rating: Analyzing trends, analysts offer qualitative evaluations, ranging from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of Elanco Animal Health compared to the broader market.</li>
<li>Price Targets: Analysts predict movements in price targets, offering estimates for Elanco Animal Health's future value. Examining the current and prior targets offers insights into analysts' evolving expectations.</li>
</ul>
Understanding these analyst evaluations alongside key financial indicators can offer valuable insights into Elanco Animal Health's market standing. Stay informed and make well-considered decisions with our Ratings Table.
<a href="https://www.benzinga.com/quote/ELAN/analyst-ratings?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Stay up to date on Elanco Animal Health analyst ratings.</a>
<h2>Delving into Elanco Animal Health's Background</h2>
Elanco Animal Health is an animal health company that is engaged in developing, manufacturing, and marketing pharma products for companion and food animals. It spun off from Eli Lilly in 2018 and acquired Janssen Animal Health in 2011, Novartis Animal Health in 2014, Boehringer Ingelheim Vetmedica in 2017, and Bayer Animal Health in 2020. The company's operations are conducted globally, and it sells its products in over 90 countries. It offers a range of food animal products used in cattle, sheep, goats, and swine production.
<h3>Unraveling the Financial Story of Elanco Animal Health</h3>
Market Capitalization Perspectives: The company's market capitalization falls below industry averages, signaling a relatively smaller size compared to peers. This positioning may be influenced by factors such as perceived growth potential or operational scale.
Revenue Growth: Elanco Animal Health's revenue growth over a period of 3M has faced challenges. As of 31 March, 2025, the company experienced a revenue decline of approximately -1.0%. This indicates a decrease in the company's top-line earnings. As compared to competitors, the company encountered difficulties, with a growth rate lower than the average among peers in the Health Care sector.
Net Margin: Elanco Animal Health's net margin falls below industry averages, indicating challenges in achieving strong profitability. With a net margin of 5.62%, the company may face hurdles in effective cost management.
Return on Equity (ROE): The company's ROE is below industry benchmarks, signaling potential difficulties in efficiently using equity capital. With an ROE of 1.08%, the company may need to address challenges in generating satisfactory returns for shareholders.
Return on Assets (ROA): Elanco Animal Health's ROA is below industry averages, indicating potential challenges in efficiently utilizing assets. With an ROA of 0.52%, the company may face hurdles in achieving optimal financial returns.
Debt Management: Elanco Animal Health's debt-to-equity ratio is below the industry average. With a ratio of 0.69, the company relies less on debt financing, maintaining a healthier balance between debt and equity, which can be viewed positively by investors.
<h2>The Core of Analyst Ratings: What Every Investor Should Know</h2>
Analysts are specialists within banking and financial systems that typically report for specific stocks or within defined sectors. These people research company financial statements, sit in conference calls and meetings, and speak with relevant insiders to determine what are known as analyst ratings for stocks. Typically, analysts will rate each stock once a quarter. 
Analysts may enhance their evaluations by incorporating forecasts for metrics like growth estimates, earnings, and revenue, delivering additional guidance to investors. It is vital to acknowledge that, although experts in stocks and sectors, analysts are human and express their opinions when providing insights.
Breaking: Wall Street's Next Big Mover
Benzinga's #1 analyst just identified a stock poised for explosive growth. This under-the-radar company could surge 200%+ as major market shifts unfold. <a href="https://www.benzinga.com/premium/ideas/turning-point-trader-checkout-2/?t=Tu1tu3arja3be22tu36&amp;adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantag">Click here for urgent details</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Analyst Ratings

ELAN

The Analyst Verdict: Elanco Animal Health In The Eyes Of 4 Experts

In the last three months, 14 analysts have published ratings on Blackstone (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BX#NYSE">BX</a>), offering a diverse range of perspectives from bullish to bearish.
The table below provides a concise overview of recent ratings by analysts, offering insights into the changing sentiments over the past 30 days and drawing comparisons with the preceding months for a holistic perspective.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">3</td>
<td align="right">3</td>
<td align="right">8</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">3</td>
<td align="right">3</td>
<td align="right">6</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
Analysts have recently evaluated Blackstone and provided 12-month price targets. The average target is $152.79, accompanied by a high estimate of $207.00 and a low estimate of $129.00. Observing a downward trend, the current average is 13.11% lower than the prior average price target of $175.85. 
<img src="https://www.benzinga.com/files/images/story/2025/1751487483_0.png" alt="price target chart" />
<h2>Interpreting Analyst Ratings: A Closer Look</h2>
In examining recent analyst actions, we gain insights into how financial experts perceive Blackstone. The following summary outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Crispin Love</td>
<td>Piper Sandler</td>
<td>Raises</td>
<td>Neutral</td>
<td>$157.00</td>
<td>$140.00</td>
</tr>
<tr>
<td>Michael Brown</td>
<td>Wells Fargo</td>
<td>Raises</td>
<td>Equal-Weight</td>
<td>$153.00</td>
<td>$139.00</td>
</tr>
<tr>
<td>Brian McKenna</td>
<td>JMP Securities</td>
<td>Maintains</td>
<td>Market Outperform</td>
<td>$165.00</td>
<td>$165.00</td>
</tr>
<tr>
<td>Brennan Hawken</td>
<td>UBS</td>
<td>Lowers</td>
<td>Buy</td>
<td>$175.00</td>
<td>$180.00</td>
</tr>
<tr>
<td>Michael Brown</td>
<td>Keefe, Bruyette &amp; Woods</td>
<td>Lowers</td>
<td>Market Perform</td>
<td>$139.00</td>
<td>$141.00</td>
</tr>
<tr>
<td>Benjamin Budish</td>
<td>Barclays</td>
<td>Raises</td>
<td>Equal-Weight</td>
<td>$136.00</td>
<td>$129.00</td>
</tr>
<tr>
<td>Michael Cyprys</td>
<td>Morgan Stanley</td>
<td>Lowers</td>
<td>Overweight</td>
<td>$150.00</td>
<td>$222.00</td>
</tr>
<tr>
<td>Bill Katz</td>
<td>TD Cowen</td>
<td>Lowers</td>
<td>Buy</td>
<td>$147.00</td>
<td>$233.00</td>
</tr>
<tr>
<td>Michael Brown</td>
<td>Wells Fargo</td>
<td>Lowers</td>
<td>Equal-Weight</td>
<td>$139.00</td>
<td>$160.00</td>
</tr>
<tr>
<td>Chris Allen</td>
<td>Citigroup</td>
<td>Lowers</td>
<td>Neutral</td>
<td>$137.00</td>
<td>$190.00</td>
</tr>
<tr>
<td>Devin Ryan</td>
<td>JMP Securities</td>
<td>Announces</td>
<td>Market Outperform</td>
<td>$165.00</td>
<td>-</td>
</tr>
<tr>
<td>Crispin Love</td>
<td>Piper Sandler</td>
<td>Lowers</td>
<td>Neutral</td>
<td>$140.00</td>
<td>$182.00</td>
</tr>
<tr>
<td>Benjamin Budish</td>
<td>Barclays</td>
<td>Lowers</td>
<td>Equal-Weight</td>
<td>$129.00</td>
<td>$186.00</td>
</tr>
<tr>
<td>Craig Siegenthaler</td>
<td>B of A Securities</td>
<td>Lowers</td>
<td>Buy</td>
<td>$207.00</td>
<td>$219.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: In response to dynamic market conditions and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their reaction to recent developments related to Blackstone. This insight gives a snapshot of analysts' perspectives on the current state of the company.</li>
<li>Rating: Providing a comprehensive analysis, analysts offer qualitative assessments, ranging from 'Outperform' to 'Underperform'. These ratings reflect expectations for the relative performance of Blackstone compared to the broader market.</li>
<li>Price Targets: Analysts navigate through adjustments in price targets, providing estimates for Blackstone's future value. Comparing current and prior targets offers insights into analysts' evolving expectations.</li>
</ul>
Considering these analyst evaluations in conjunction with other financial indicators can offer a comprehensive understanding of Blackstone's market position. Stay informed and make well-informed decisions with our Ratings Table.
<a href="https://www.benzinga.com/quote/BX/analyst-ratings?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Stay up to date on Blackstone analyst ratings.</a>
<h2>Discovering Blackstone: A Closer Look</h2>
Blackstone is the world's largest alternative-asset manager with $1.167 trillion in total asset under management, including $860.1 billion in fee-earning assets under management, at the end of March 2025. The company has four core business segments: private equity (26% of fee-earning AUM and 30% of base management fees), real estate (34% and 40%), credit and insurance (32% and 23%), and multi-asset investing (8% and 7%). While the firm primarily serves institutional investors (87% of AUM), it also caters to clients in the high-net-worth channel (13%). Blackstone operates through 25 offices in the Americas (8), Europe and the Middle East (9), and the Asia-Pacific region (8).
<h3>Blackstone: Financial Performance Dissected</h3>
Market Capitalization: Positioned above industry average, the company's market capitalization underscores its superiority in size, indicative of a strong market presence.
Revenue Growth: Blackstone's revenue growth over a period of 3M has faced challenges. As of 31 March, 2025, the company experienced a revenue decline of approximately -7.28%. This indicates a decrease in the company's top-line earnings. As compared to its peers, the revenue growth lags behind its industry peers. The company achieved a growth rate lower than the average among peers in Financials sector.
Net Margin: Blackstone's net margin falls below industry averages, indicating challenges in achieving strong profitability. With a net margin of 21.75%, the company may face hurdles in effective cost management.
Return on Equity (ROE): Blackstone's ROE stands out, surpassing industry averages. With an impressive ROE of 7.6%, the company demonstrates effective use of equity capital and strong financial performance.
Return on Assets (ROA): Blackstone's ROA surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive 1.39% ROA, the company effectively utilizes its assets for optimal returns.
Debt Management: Blackstone's debt-to-equity ratio surpasses industry norms, standing at 1.68. This suggests the company carries a substantial amount of debt, posing potential financial challenges.
<h2>Analyst Ratings: Simplified</h2>
Ratings come from analysts, or specialists within banking and financial systems that report for specific stocks or defined sectors (typically once per quarter for each stock). Analysts usually derive their information from company conference calls and meetings, financial statements, and conversations with important insiders to reach their decisions.
Analysts may supplement their ratings with predictions for metrics like growth estimates, earnings, and revenue, offering investors a more comprehensive outlook. However, investors should be mindful that analysts, like any human, can have subjective perspectives influencing their forecasts.
Breaking: Wall Street's Next Big Mover
Benzinga's #1 analyst just identified a stock poised for explosive growth. This under-the-radar company could surge 200%+ as major market shifts unfold. <a href="https://www.benzinga.com/premium/ideas/turning-point-trader-checkout-2/?t=Tu1tu3arja3be22tu36&amp;adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantag">Click here for urgent details</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Breaking Down Blackstone: 14 Analysts Share Their Views

13 analysts have expressed a variety of opinions on Apellis Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/APLS#NASDAQ">APLS</a>) over the past quarter, offering a diverse set of opinions from bullish to bearish.
The following table encapsulates their recent ratings, offering a glimpse into the evolving sentiments over the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">2</td>
<td align="right">3</td>
<td align="right">8</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">2</td>
<td align="right">2</td>
<td align="right">5</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
The 12-month price targets assessed by analysts reveal further insights, featuring an average target of $30.46, a high estimate of $52.00, and a low estimate of $18.00. Highlighting a 17.68% decrease, the current average has fallen from the previous average price target of $37.00. 
<img src="https://www.benzinga.com/files/images/story/2025/1751487475_0.png" alt="price target chart" />
<h2>Diving into Analyst Ratings: An In-Depth Exploration</h2>
A comprehensive examination of how financial experts perceive Apellis Pharmaceuticals is derived from recent analyst actions. The following is a detailed summary of key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Judah Frommer</td>
<td>Morgan Stanley</td>
<td>Raises</td>
<td>Equal-Weight</td>
<td>$26.00</td>
<td>$25.00</td>
</tr>
<tr>
<td>Derek Archila</td>
<td>Wells Fargo</td>
<td>Raises</td>
<td>Equal-Weight</td>
<td>$29.00</td>
<td>$26.00</td>
</tr>
<tr>
<td>Yigal Nochomovitz</td>
<td>Citigroup</td>
<td>Lowers</td>
<td>Buy</td>
<td>$41.00</td>
<td>$49.00</td>
</tr>
<tr>
<td>Graig Suvannavejh</td>
<td>Mizuho</td>
<td>Lowers</td>
<td>Neutral</td>
<td>$20.00</td>
<td>$30.00</td>
</tr>
<tr>
<td>Ryan Deschner</td>
<td>Raymond James</td>
<td>Lowers</td>
<td>Outperform</td>
<td>$52.00</td>
<td>$75.00</td>
</tr>
<tr>
<td>Tazeen Ahmad</td>
<td>B of A Securities</td>
<td>Lowers</td>
<td>Neutral</td>
<td>$23.00</td>
<td>$41.00</td>
</tr>
<tr>
<td>Luca Issi</td>
<td>RBC Capital</td>
<td>Lowers</td>
<td>Sector Perform</td>
<td>$18.00</td>
<td>$21.00</td>
</tr>
<tr>
<td>Greg Harrison</td>
<td>Scotiabank</td>
<td>Lowers</td>
<td>Sector Perform</td>
<td>$20.00</td>
<td>$28.00</td>
</tr>
<tr>
<td>Derek Archila</td>
<td>Wells Fargo</td>
<td>Lowers</td>
<td>Equal-Weight</td>
<td>$26.00</td>
<td>$30.00</td>
</tr>
<tr>
<td>Colleen Kusy</td>
<td>Baird</td>
<td>Lowers</td>
<td>Outperform</td>
<td>$47.00</td>
<td>$55.00</td>
</tr>
<tr>
<td>Joseph Stringer</td>
<td>Needham</td>
<td>Lowers</td>
<td>Buy</td>
<td>$29.00</td>
<td>$40.00</td>
</tr>
<tr>
<td>Eliana Merle</td>
<td>Cantor Fitzgerald</td>
<td>Announces</td>
<td>Overweight</td>
<td>$44.00</td>
<td>-</td>
</tr>
<tr>
<td>Luca Issi</td>
<td>RBC Capital</td>
<td>Lowers</td>
<td>Sector Perform</td>
<td>$21.00</td>
<td>$24.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Analysts respond to changes in market conditions and company performance, frequently updating their recommendations. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to Apellis Pharmaceuticals. This information offers a snapshot of how analysts perceive the current state of the company.</li>
<li>Rating: Delving into assessments, analysts assign qualitative values, from 'Outperform' to 'Underperform'. These ratings communicate expectations for the relative performance of Apellis Pharmaceuticals compared to the broader market.</li>
<li>Price Targets: Analysts navigate through adjustments in price targets, providing estimates for Apellis Pharmaceuticals's future value. Comparing current and prior targets offers insights into analysts' evolving expectations.</li>
</ul>
Assessing these analyst evaluations alongside crucial financial indicators can provide a comprehensive overview of Apellis Pharmaceuticals's market position. Stay informed and make well-judged decisions with the assistance of our Ratings Table.
<a href="https://www.benzinga.com/quote/APLS/analyst-ratings?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Stay up to date on Apellis Pharmaceuticals analyst ratings.</a>
<h2>Get to Know Apellis Pharmaceuticals Better</h2>
Apellis Pharmaceuticals Inc is a commercial-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel therapeutic compounds to treat diseases with high unmet needs through the inhibition of the complement system, which is an integral component of the immune system, at the level of C3, the central protein in the complement cascade.
<h3>Apellis Pharmaceuticals's Economic Impact: An Analysis</h3>
Market Capitalization Analysis: The company's market capitalization is below the industry average, suggesting that it is relatively smaller compared to peers. This could be due to various factors, including perceived growth potential or operational scale.
Revenue Challenges: Apellis Pharmaceuticals's revenue growth over 3M faced difficulties. As of 31 March, 2025, the company experienced a decline of approximately -3.21%. This indicates a decrease in top-line earnings. In comparison to its industry peers, the company trails behind with a growth rate lower than the average among peers in the Health Care sector.
Net Margin: Apellis Pharmaceuticals's net margin excels beyond industry benchmarks, reaching -55.29%. This signifies efficient cost management and strong financial health.
Return on Equity (ROE): Apellis Pharmaceuticals's ROE is below industry standards, pointing towards difficulties in efficiently utilizing equity capital. With an ROE of -46.96%, the company may encounter challenges in delivering satisfactory returns for shareholders.
Return on Assets (ROA): Apellis Pharmaceuticals's ROA lags behind industry averages, suggesting challenges in maximizing returns from its assets. With an ROA of -10.9%, the company may face hurdles in achieving optimal financial performance.
Debt Management: With a high debt-to-equity ratio of 2.86, Apellis Pharmaceuticals faces challenges in effectively managing its debt levels, indicating potential financial strain.
<h2>The Significance of Analyst Ratings Explained</h2>
Analysts are specialists within banking and financial systems that typically report for specific stocks or within defined sectors. These people research company financial statements, sit in conference calls and meetings, and speak with relevant insiders to determine what are known as analyst ratings for stocks. Typically, analysts will rate each stock once a quarter. 
Beyond their standard evaluations, some analysts contribute predictions for metrics like growth estimates, earnings, and revenue, furnishing investors with additional guidance. Users of analyst ratings should be mindful that this specialized advice is shaped by human perspectives and may be subject to variability.
Breaking: Wall Street's Next Big Mover
Benzinga's #1 analyst just identified a stock poised for explosive growth. This under-the-radar company could surge 200%+ as major market shifts unfold. <a href="https://www.benzinga.com/premium/ideas/turning-point-trader-checkout-2/?t=Tu1tu3arja3be22tu36&amp;adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantag">Click here for urgent details</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

APLS

What 13 Analyst Ratings Have To Say About Apellis Pharmaceuticals

Inovio shares are trading lower after the company announced a proposed public offering.

On June 3, 2025, a director of Baosheng Media Group Holdings Limited (the "Company") was served with a complaint filed by three institutional investors (the "Plaintiffs") in the Beijing Fourth Intermediate People's Court. The Plaintiffs allege that five defendants, including the director, engaged in corporate mismanagement that caused a significant decline in the value of the Company's stock held by the Plaintiffs, resulting in substantial investment losses. The Plaintiffs are seeking damages of RMB 47,249,848 (approximately US$6.59 million). The five defendants have retained legal counsel to file their defense.

Legal

BAOS

Baosheng Media Director Named In ~$6.6M Lawsuit By Institutional Investors Alleging Corporate Mismanagement

Contracts

Press Releases

UTime Limited Partners with Dr. Ehud Baron to Pioneer AI-Driven Health Solutions

UTime Limited Announces Ambitious AI Health Strategy and Strategic Collaboration

UTime Limited to Participate in International Medical Fairs and Medical Conferences

About Circul VS: A Core Continuous Blood Pressure Measurement Technology System Developed in Partnership with Dr. Ehud Baron

UTime Signs NDA to Acquire Monkeypox Vaccine Maker Bowen Therapeutics Inc and Supports Completion of FDA Registration of Related Vaccines

Remarkable Announcement on Significant Fluctuation of the UTime's Share Price

Markets

UTime Limited Announces 1-For-25 Reverse Share Split

UTime Limited Announces Pricing of $5 Million Registered Direct Offering

UTime Limited Received Nasdaq Notification Letter Regarding Bid Price Deficiency

UTime Limited Announces 1-For-10 Reverse Share Split

Comments

UTime

Vendite allo scoperto

UTime (NASDAQ:WTO) Azioni, Report sulle vendite allo scoperto

Notizie

PARTNER/COLLABORATORE

BENZINGA NEL MONDO